Prediabetes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others), By Age Group (Children (12-18 years), Adults (18-49), Elderly (50+)), By Region and Competition, 2020-2030F

Market Overview

Global Prediabetes Market was valued at USD 324.51 Million in 2024 and is expected to reach USD 608.46 Million in the forecast period with a CAGR of 11.02% through 2030. The Global Prediabetes Market is gaining traction as healthcare systems increasingly prioritize early intervention strategies to manage the growing burden of chronic metabolic conditions. Prediabetes, characterized by elevated blood glucose levels that are not yet high enough for a diabetes diagnosis, is receiving increased attention due to its strong correlation with type 2 diabetes and cardiovascular risks. As awareness around early detection and intervention grows, there is a noticeable rise in screenings and diagnostic assessments, particularly among high-risk populations. This is driving demand for oral antihyperglycemic agents, nutritional supplements, and lifestyle management programs tailored to prediabetic individuals. The integration of preventive healthcare into standard clinical practice, supported by collaborations between public health agencies and private stakeholders, is strengthening the market’s foundation.

Growing awareness about the importance of proactive disease management and the availability of innovative tools for blood glucose monitoring and lifestyle tracking are key growth drivers. Wearable health devices, mobile health apps, and continuous glucose monitoring systems are enabling patients and providers to track health metrics in real-time, leading to more personalized treatment approaches. Technological innovation in predictive diagnostics, including the use of biomarkers and AI-powered risk assessment tools, is also shaping the future of prediabetes care. These advancements are encouraging the development of targeted therapies and digital health platforms that not only support glycemic control but also promote holistic metabolic wellness. Market players are responding by expanding product portfolios and entering strategic partnerships aimed at integrating pharmaceutical, nutritional, and behavioral solutions.

Despite strong growth potential, the market faces several challenges. Low awareness and limited access to diagnostic facilities in low-income settings are major barriers to early detection. Many individuals remain undiagnosed due to a lack of symptoms in the prediabetic stage, resulting in delayed intervention. Another key challenge is the absence of standardized treatment protocols for prediabetes, which limits the adoption of therapeutic products. Inconsistent reimbursement policies for preventive care further impact product uptake, especially in cost-sensitive markets. Lifestyle modification remains the primary recommendation, but ensuring long-term patient compliance without structured programs poses a hurdle. Even as technology-driven solutions are emerging, data privacy concerns and integration issues with existing health systems may slow down adoption. Addressing these obstacles through policy support, patient education, and clinical innovation will be critical to unlocking the full potential of the Global Prediabetes Market.

Key Market Drivers

Increasing Prevalence of Lifestyle-Related Risk Factors

​The Global Prediabetes Market is experiencing significant growth, primarily driven by the escalating prevalence of lifestyle-related risk factors that contribute to the increasing number of individuals at risk of developing type 2 diabetes. Unhealthy dietary habits, physical inactivity, rising obesity rates, and high stress levels have become widespread, particularly in urban areas where sedentary jobs and the consumption of processed foods are prevalent. These behaviors lead to metabolic imbalances, insulin resistance, and elevated blood glucose levels, making individuals more susceptible to prediabetes. The rapid pace of urbanization and modernization has altered traditional lifestyles, encouraging habits that negatively impact glucose metabolism and weight management. Notably, younger age groups are increasingly being diagnosed with prediabetic conditions due to early exposure to processed foods, sugary beverages, irregular sleep cycles, and limited physical activity.​

Recent statistics underscore the severity of these trends. According to the National Diabetes Statistics Report by the Centers for Disease Control and Prevention (CDC), more than one in three American adults have prediabetes. Furthermore, data from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) reveals that over 42.4% of U.S. adults have obesity, a significant increase over the past few decades. Physical inactivity also remains a critical concern, with only 25% of adults meeting the recommended physical activity guidelines. These factors collectively contribute to the rising incidence of prediabetes, emphasizing the urgent need for effective preventive measures.​

Growing consumer awareness about the link between these lifestyle patterns and chronic diseases is prompting more individuals to seek early intervention through screenings and preventive health services. Healthcare providers are recognizing the importance of identifying at-risk individuals before they progress to full-blown diabetes, driving investments in early detection tools and wellness programs. Governments and public health bodies are also rolling out national campaigns to raise awareness about lifestyle-induced metabolic risks. These initiatives are further supported by the rise of digital health platforms, mobile apps, and wearable devices that help users track physical activity, calorie intake, and blood sugar levels. This growing ecosystem of tools and services is reinforcing proactive health management and timely medical consultation. With prediabetes now recognized as a critical phase for intervention, the surge in lifestyle-related risk factors is pushing both patients and healthcare stakeholders to act earlier, fueling consistent demand for diagnostic services, lifestyle coaching, and pharmacological solutions aimed at controlling the condition. This dynamic is expected to remain a key market driver in the coming years.​

Advancements in Diagnostic and Monitoring Technologies

Advancements in diagnostic and monitoring technologies are significantly propelling the growth of the Global Prediabetes Market. The Centers for Disease Control and Prevention (CDC) reports that approximately 98 million American adults more than one in three have prediabetes, with over 80% unaware of their condition. This substantial prevalence underscores the urgent need for improved diagnostic tools. Innovations such as continuous glucose monitoring (CGM) systems, HbA1c testing devices, portable glucometers, and AI-powered digital screening tools have markedly enhanced the early detection of glucose irregularities, often before clinical symptoms of diabetes manifest. These technologies not only improve diagnostic accuracy but also enable healthcare professionals to initiate early interventions and personalized treatment strategies.​

The integration of mobile health applications and wearable devices further augments monitoring efforts, allowing users to track real-time glucose fluctuations, physical activity, dietary habits, and sleep patterns. This continuous data feedback loop empowers patients to make lifestyle modifications that can delay or prevent the progression to type 2 diabetes. Given that the CDC highlights lifestyle changes can cut the risk of developing type 2 diabetes in half, the role of advanced monitoring technologies becomes even more critical in facilitating these preventive measures.​

Technology-enabled platforms also facilitate remote patient monitoring, teleconsultations, and automated risk assessments, which are crucial in improving healthcare accessibility in underserved or rural areas. Healthcare providers are increasingly leveraging cloud-based systems and electronic health records to track longitudinal health trends, enabling data-driven decision-making and population-level disease management. In urban settings, tech-savvy consumers are adopting these innovations as part of wellness and preventive health programs, contributing to growing consumer demand for home-based diagnostic solutions. Strategic partnerships between diagnostics companies, health tech firms, and healthcare institutions are accelerating the development and distribution of cost-effective, user-friendly diagnostic solutions, making prediabetes screening more scalable and inclusive. These advancements are not only reshaping patient engagement but also attracting investment in early-stage diagnostics, marking a significant shift toward proactive healthcare. As technology continues to evolve, the early and accurate detection of prediabetes will remain a key driver shaping the market’s expansion in the coming years.

Increase in Healthcare Spending and Insurance Coverage for Preventive Services

​The Global Prediabetes Market is experiencing significant growth, driven by increased healthcare spending and expanded insurance coverage for preventive services. Governments and private health insurers worldwide are recognizing the substantial economic and social burdens posed by chronic diseases like type 2 diabetes and are shifting their focus toward prevention and early intervention. This strategic shift has led to enhanced funding for public health campaigns, screening programs, and subsidized diagnostic services targeting early-stage metabolic disorders, including prediabetes. The escalating costs associated with managing full-blown diabetes and its complications have prompted stakeholders to invest in cost-effective preventive measures that can reduce long-term healthcare expenditures.​

To address this, health insurance providers are increasingly covering screenings, laboratory tests, and consultations related to prediabetes as part of their preventive care offerings. This development has made it more accessible for individuals to obtain diagnostic and lifestyle counseling services without bearing the full financial burden. Health systems are also emphasizing lifestyle modification programs, such as diet and exercise counseling, weight management support, and digital health tools, which are increasingly included under insurance plans. This broader access to preventive services encourages early detection and management of prediabetes, thereby reducing progression to type 2 diabetes.​

Increased healthcare funding has also facilitated the growth of public awareness campaigns and the integration of risk assessment tools in primary care settings. Digital health platforms and mobile applications, funded or reimbursed through public-private partnerships, are making personalized prediabetes management more accessible. This shift is improving early detection rates and driving demand for diagnostic kits, oral hypoglycemic agents, nutritional supplements, and health monitoring services. As healthcare systems continue to expand preventive care infrastructure and policies, the market for prediabetes solutions is set to experience sustained growth, driven by greater access, affordability, and proactive patient participation.

Download Free Sample Report

Key Market Challenges

Lack of Awareness and Underdiagnosis

One of the most pressing challenges facing the Global Prediabetes Market is the persistent lack of awareness and widespread underdiagnosis, which significantly hampers early intervention and disease management efforts. Prediabetes is often asymptomatic, and many individuals remain unaware of their condition until it progresses to type 2 diabetes or leads to serious complications. This silent progression is a major concern, particularly in low- and middle-income countries where access to routine health checkups and diagnostic services is limited. Even in developed regions, public knowledge about prediabetes and its long-term risks remains inadequate, leading to delayed testing and missed opportunities for preventive care. Many people associate diabetes with advanced stages only, overlooking the critical window for intervention during the prediabetic phase.

Healthcare systems also contribute to the underdiagnosis due to a lack of standardized screening protocols and inconsistent application of risk assessment guidelines among general practitioners. In many clinical settings, blood glucose testing is not routinely performed unless the patient is already displaying obvious symptoms or has known risk factors. This reactive rather than proactive approach to disease identification leads to millions of individuals living with prediabetes without proper management. The absence of public health campaigns on par with those for cardiovascular or infectious diseases means prediabetes does not receive the attention it urgently requires. This gap delays diagnosis and increases the likelihood of long-term complications, raising the burden on healthcare infrastructures. To overcome this challenge, coordinated efforts involving policymakers, healthcare providers, and community outreach programs are essential to raise awareness, promote routine screenings, and ensure early identification of those at risk. Addressing this issue is vital not only to reduce the transition to diabetes but also to unlock the full potential of the growing market for diagnostics, therapeutics, and lifestyle management solutions targeted at prediabetic individuals.

Absence of Standardized Treatment Protocols

The absence of standardized treatment protocols remains a critical challenge in the Global Prediabetes Market, limiting the effectiveness and consistency of care across different healthcare settings. Prediabetes exists in a grey area between normal glucose metabolism and diabetes, and the lack of universally accepted clinical guidelines for its diagnosis and management often leads to varied approaches among healthcare professionals. Some practitioners focus on lifestyle interventions, such as diet and physical activity modifications, while others may opt for pharmacological treatment, particularly in high-risk patients. This inconsistency results in a fragmented care pathway, where patients may receive differing advice or therapies depending on the provider or region, ultimately affecting patient outcomes and delaying the reversal or prevention of disease progression.

Healthcare systems across the globe also differ in how they classify and respond to prediabetes, with no single diagnostic threshold or treatment algorithm that is universally followed. This lack of uniformity complicates large-scale screening programs, creates confusion among patients, and presents obstacles for pharmaceutical companies developing targeted therapies. The absence of consensus also hinders clinical research, making it difficult to compare results across studies or conduct multi-country trials. As a result, payers and policymakers may be hesitant to allocate resources or reimburse interventions without clearly defined and evidence-backed protocols. Addressing this challenge will require coordinated efforts from international health authorities, clinical researchers, and healthcare organizations to establish standardized, evidence-based treatment frameworks that can guide both prevention and early intervention strategies for prediabetes. Without such protocols, scaling solutions and ensuring consistent care delivery across populations will remain a persistent barrier in managing the growing global prediabetes burden.

Key Market Trends

Rising Integration of Digital Therapeutics (DTx) and Mobile Health Platforms

The rising integration of digital therapeutics (DTx) and mobile health platforms is significantly transforming the landscape of the Global Prediabetes Market. As healthcare systems shift toward preventive and personalized care, digital tools are emerging as powerful solutions for managing chronic metabolic conditions like prediabetes. Digital therapeutics are evidence-based software applications that deliver structured interventions to modify patient behavior, monitor glycemic trends, and support lifestyle changes. These platforms enable users to track physical activity, nutrition, sleep, and stress key factors in preventing the progression of prediabetes to type 2 diabetes. Many of these tools integrate seamlessly with wearable devices and continuous glucose monitors, offering real-time feedback and data-driven insights to both users and healthcare professionals. The convenience of remote access to coaching, educational content, and personalized plans has increased user engagement and compliance, especially among tech-savvy younger demographics and urban populations.

As smartphone penetration and internet access expand globally, mobile health platforms are becoming more accessible in both developed and emerging markets. These platforms not only improve patient outcomes but also reduce the burden on traditional healthcare infrastructure by decreasing the need for frequent in-person visits. Regulatory approvals and clinical validation of several digital therapeutics have enhanced trust among healthcare providers and payers, leading to greater adoption. Insurance companies and corporate wellness programs are beginning to reimburse or subsidize DTx tools, recognizing their cost-effectiveness in long-term disease management. As the demand for non-invasive, scalable, and personalized solutions grows, digital therapeutics and mobile platforms are poised to become essential components in early prediabetes intervention. This trend is expected to accelerate innovation, improve health literacy, and empower individuals to take greater control over their metabolic health through proactive engagement and preventive strategies. The integration of artificial intelligence and machine learning into these platforms is further enhancing predictive accuracy and personalized care pathways in prediabetes management.

Growing Adoption of Point-of-Care Testing and At-Home Diagnostics

The Global Prediabetes Market is witnessing a significant trend toward the adoption of point-of-care (POC) testing and at-home diagnostics, driven by the increasing demand for accessible, timely, and user-friendly health monitoring solutions. With the growing prevalence of prediabetes across diverse populations, early detection has become critical in preventing the progression to type 2 diabetes. Traditional diagnostic approaches that require lab visits, appointments, and waiting periods often lead to delays in diagnosis and intervention. In contrast, POC devices and home-based test kits offer immediate results, allowing users to monitor blood glucose levels, HbA1c, and other metabolic indicators conveniently from their homes. This shift is particularly impactful in rural and underserved areas, where access to diagnostic laboratories may be limited or delayed due to infrastructure constraints.

Technological advancements in miniaturized biosensors, smartphone integration, and connected health platforms have fueled the development of accurate, easy-to-use prediabetes testing kits. Consumers are becoming more health-conscious and proactive, seeking tools that empower them to take control of their metabolic health. This trend is also supported by the rise of telemedicine, where test results can be seamlessly shared with healthcare providers for remote consultation and personalized guidance. Healthcare companies and startups are investing in user-centric diagnostic solutions that combine affordability with real-time analytics, enabling early intervention and better disease management. Payers and health systems are recognizing the value of these tools in reducing long-term healthcare costs by minimizing complications associated with undiagnosed prediabetes. Public health campaigns are also promoting self-monitoring and regular screening as part of broader diabetes prevention strategies. As awareness grows and digital health infrastructure improves, the market is expected to see continued growth in demand for POC testing and at-home diagnostic solutions, transforming the way prediabetes is detected and managed on a global scale.

Segmental Insights

Drug Class Insights

Based on the Drug Class, Biguanide emerged as the dominant segment in the Global Prediabetes Market in 2024. This is due to its proven efficacy, affordability, and widespread clinical acceptance. Metformin, the primary biguanide used in prediabetes management, remains the first-line pharmacological intervention recommended by numerous international diabetes associations. Its mechanism of action—enhancing insulin sensitivity and reducing hepatic glucose production—makes it particularly effective for delaying or preventing the progression from prediabetes to type 2 diabetes. The drug has a well-established safety profile and is often prescribed alongside lifestyle interventions, especially for patients who are overweight or have additional risk factors. Its relatively low cost compared to newer classes of antidiabetic medications has further supported its dominance, particularly in price-sensitive and resource-limited markets. Clinical studies have consistently shown that metformin can reduce the risk of developing type 2 diabetes by 30–40% in high-risk individuals, making it a widely adopted option among healthcare providers.

Age Group Insights

Based on the Age Group, Adults (18-49) emerged as the dominant segment in the Global Prediabetes Market in 2024. This is driven by the rising prevalence of lifestyle-related risk factors among this demographic. Increased consumption of high-calorie diets, sedentary routines linked to urbanization and digitalization, and mounting stress levels have contributed to a growing number of young and middle-aged adults developing insulin resistance and impaired glucose tolerance. This age group is also more likely to undergo routine health screenings, workplace wellness programs, and digital health tracking, which aid in early detection and diagnosis of prediabetes. As healthcare providers focus more on prevention and long-term health outcomes, there is a growing emphasis on intervening early particularly in younger populations to delay or prevent the onset of type 2 diabetes. The growing adoption of fitness wearables, health apps, and telemedicine platforms among adults aged 18–49 has further enabled proactive monitoring and lifestyle management, supporting their early diagnosis and engagement in preventive care.

Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the Global Prediabetes Market in 2024. This is due to the high prevalence of obesity, sedentary lifestyles, and poor dietary habits, which are key risk factors contributing to the rising incidence of prediabetes. According to the Centers for Disease Control and Prevention (CDC), an estimated 99 million adults in the United States had prediabetes as of 2023, accounting for more than one in three American adults. The region has strong healthcare infrastructure, widespread access to diagnostic services, and significant investment in public awareness campaigns, all of which support early detection and intervention. The dominance of North America is also driven by the adoption of digital health platforms, remote patient monitoring, and advanced diagnostic technologies that enable proactive management of metabolic health. Numerous government and private initiatives, such as the National Diabetes Prevention Program (NDPP), emphasize preventive care and patient education, which further strengthen early engagement with at-risk populations.

Asia-Pacific emerged as the fastest growing region in the Global Prediabetes Market during the forecast period. This is due to the rapidly increasing prevalence of lifestyle-related disorders and urbanization-driven changes in dietary and physical activity patterns. Countries such as India, China, and Indonesia are witnessing a surge in sedentary behaviors, high sugar consumption, and growing obesity rates, all of which are major contributors to insulin resistance and elevated blood glucose levels. As younger populations in these countries become more susceptible to metabolic disorders due to unhealthy eating habits and reduced physical activity, the demand for early diagnosis and intervention for prediabetes is rising significantly. National governments and health authorities are increasingly recognizing the burden of prediabetes as a public health concern and are initiating nationwide screening and prevention programs to curb the onset of type 2 diabetes.

Recent Developments

• In March 2025, Sigrid Therapeutics secured U.S. market access for its SiPore technology after the successful SHINE study, the largest clinical trial in prediabetes. The study confirmed that Carb Fence, a medical-grade liquid formula using SiPore, significantly lowers HbA1c levels, enhances glucose metabolism, and supports weight loss without compromising muscle mass. With these results, Carb Fence™ is now positioned as an FDA-recognized medical food for physician-supervised dietary management of prediabetes.
• In November 2024, Redcliffe Labs launched a digital Prediabetes Risk Checker tool through its Android app to support early diagnosis and preventive care. Introduced on World Diabetes Day as part of the company’s “Beat the Sugar Trap” campaign, the tool leverages data analytics to assess an individual’s risk based on lifestyle and genetic inputs. Redcliffe Labs’ initiative reflects a broader push toward tech-enabled, preventive healthcare solutions targeting the country’s rising prediabetes population, particularly among younger, urban demographics.
• In September 2024, Dexcom, in collaboration with nonprofit Beyond Type 2 and actress Retta, launched National Glucose Awareness Week (Sept. 23–29) to raise awareness about glucose health and bridge the knowledge gap among people with diabetes and prediabetes. The initiative responds to a recent survey revealing that only 10% of individuals with Type 2 diabetes or prediabetes fully understand what affects their glucose levels, while 45% reported confusion in managing their condition and 50% experienced a decline in confidence about their overall health.
• In August 2024, Eli Lilly and Company announced that tirzepatide (marketed as Zepbound and Mounjaro) reduced the risk of developing type 2 diabetes by 94% in adults with prediabetes and obesity or overweight, based on results from the three-year SURMOUNT-1 study. The once-weekly treatment also led to sustained weight loss, with the 15 mg dose achieving an average 22.9% reduction in body weight compared to 2.1% with placebo.
• In June 2024, Aphaia Pharma announced successful results from its Phase 2 clinical trial of APHD-012, its lead oral glucose formulation for prediabetes. The trial met its primary endpoint by demonstrating a statistically significant improvement in glucose tolerance among individuals with a pathological Oral Glucose Tolerance Test (OGTT) after six weeks of treatment. Participants receiving APHD-012 showed marked improvements compared to those on placebo, indicating the formulation’s potential to effectively modulate glucose response in prediabetic individuals. The drug also exhibited a favorable safety and tolerability profile, reinforcing its viability for further clinical development.

Key Market Players

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca
• Bristol-Myers Squibb Company
• Pfizer Inc.

Report Scope:

In this report, the Global Prediabetes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Prediabetes Market, By Drug Class:

o   Biguanide

o   Thiazolidinediones

o   Glucagon-like peptide-1 agonists (GLP-1)

o   SGLT2 inhibitors

o   DPP-4 inhibitors

o   Others

• Prediabetes Market, By Age Group:

o   Children (12-18 years)

o   Adults (18-49)

o   Elderly (50+)

• Prediabetes Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Prediabetes Market.

Available Customizations:

Global Prediabetes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Prediabetes Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com